New ProteoGenix system aims to enhance biologics development
By Jane Byrne
- Last updated on
ProteoGenix, a contract research organization (CRO) specialized in biologics discovery and bioproduction, has recently launched its XtenCHO Transient Expression System.
The developer said that, due to its enhanced plasmid stability and optimized metabolism, the new mammalian cell-based expression host achieves up to ten times higher yields with less hands-on time compared to existing solutions.
The new CHO host aims to simplify recombinant protein production and accelerate early phase drug screening.
The firm said the technology has been used and optimized by its experts for the past five years to produce over 3,500 recombinant proteins.
With the ability to perform superior protein folding and human-like post-translational modifications, the CRO said XtenCHO has proven to be ideal for the small and medium-scale production of monoclonal antibodies.
“The new XtenCHO system produces monoclonal antibodies that are indistinguishable from biopharmaceutical-grade biologics produced in stable systems. This eases process scalability and reduces the risks when transitioning from the bench to the clinic,” said Dr Raphaël Hopfner, CSO and co-founder of ProteoGenix.
“We have launched XtenCHO to help speed up the process of early drug development; making it safer, more flexible, accessible and easier to integrate into existing biologics discovery workflows using cost-effective reagents to achieve very high yields,” added Philippe Funfrock, CEO and co-founder of ProteoGenix.